Phase 3Completed
A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
- Sponsor
- Restorbio Inc. (Industry)
- Enrollment
- 1,024 enrolled
- Conditions
- Respiratory Tract Infections
- Interventions
- Dactolisib; Placebo
- Ages
- older adults
- Registry
- NCT04668352
Full record on ClinicalTrials.gov
From the registry
To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.
Primary outcomes
- Percentage of Subjects With Clinically Symptomatic Respiratory Illness
History
Results first posted
Last registry update
Registered
Primary completion
Started